13F filer · CIK 1697748 ↗

ARK Invest

Cathie WoodChief Executive Officer and Chief Investment Officer

You are looking at Q4 2022. See the latest, Q2 2026 →

Reported value

$11.54B

−20% on the quarter before

Positions

232

5 new · 23 sold out

Top 10

45.9%

of the value

Est. gain

−$1.88B

on stocks held all quarter

Est. return

−14.3%

on those stocks since Q3 2022

Filed

Jan 24, 2023

On SEC EDGAR ↗

Positions as of Dec 31, 2022, from ARK Invest's 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2022. Striped tiles are options.

208 others25%

Exact Sciences Corp6.9%

Zoom6.2%Tesla4.9%Block4.9%UiPath4.9%

Roku Inc4.3%

Shopify Inc4.0%

Teladoc Health Inc3.9%

Twilio3.1%

Intellia Therapeutics Inc2.8%

Coinbase2.8%

Beam Therapeutics Inc2.8%

Crispr Therapeutics Ag2.8%

Unity Software Inc2.7%

Draftkings Inc2.5%

Pagerduty Inc2.3%

Ginkgo Bioworks Holdings Inc2.1%

Roblox2.1%Robinhood2.1%

Pacific Biosciences Of Califor1.8%

Veracyte Inc1.7%

Twist Bioscience Corp1.4%

10x Genomics Inc1.4%

0.9%

208 others25%

Exact Sciences Corp6.9%

Zoom6.2%Tesla4.9%Block4.9%UiPath4.9%

Roku Inc4.3%

Shopify Inc4.0%

Teladoc Health Inc3.9%

Twilio3.1%

Intellia Therapeutics Inc2.8%

Coinbase2.8%

Beam Therapeutics Inc2.8%

Crispr Therapeutics Ag2.8%

Unity Software Inc2.7%

Draftkings Inc2.5%

Pagerduty Inc2.3%

Ginkgo Bioworks Holdings Inc2.1%

Roblox2.1%Robinhood2.1%

Pacific Biosciences Of Califor1.8%

Veracyte Inc1.7%

Twist Bioscience Corp1.4%

10x Genomics Inc1.4%

0.9%

Largest buys

Since Q3 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Tesla~$67.1MAdded · 7.5% → 4.9%+544,555 shares
Coinbase~$52.1MAdded · 3.5% → 2.8%+1,472,138 shares
Prime Medicine Inc~$30.5MNew · 0.0% → 0.3%+1,639,984 shares
Ginkgo Bioworks Holdings Inc~$29.7MAdded · 2.8% → 2.1%+17,565,211 shares
Twilio~$28.6MAdded · 3.3% → 3.1%+583,314 shares
Verve Therapeutics Inc~$18.8MAdded · 0.8% → 0.7%+971,971 shares
Roku Inc~$8.0MAdded · 4.7% → 4.3%+197,115 shares
Nurix Therapeutics Inc~$7.7MAdded · 0.1% → 0.2%+701,732 shares
Adobe~$7.1MAdded · 0.0% → 0.1%+21,047 shares
Compass Pathways Plc~$6.8MAdded · 0.0% → 0.1%+842,517 shares

Largest sells

Since Q3 2022, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Nvidia~$125.6MCut · 1.2% → 0.7%−859,443 shares
Exact Sciences Corp~$75.3MCut · 4.0% → 6.9%−1,521,212 shares
Fate Therapeutics Inc~$75.1MCut · 1.8% → 0.4%−7,440,970 shares
Spotify Technology Sa~$61.5MCut · 0.5% → 0.0%−778,982 shares
Signify Health Inc~$61.1MSold out · 0.4% → 0.0%−2,095,811 shares
Teladoc Health Inc~$45.6MCut · 3.7% → 3.9%−1,929,862 shares
Shopify Inc~$43.5MCut · 2.7% → 4.0%−1,253,425 shares
Ionis Pharmaceuticals Inc~$39.3MCut · 1.1% → 0.9%−1,039,569 shares
Robinhood~$29.8MCut · 2.3% → 2.1%−3,665,046 shares
Tusimple Holdings Inc~$26.3MCut · 0.9% → 0.0%−16,099,216 shares

Holdings

As of Dec 31, 2022. Changes are in shares against Sep 30, 2022, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Exact Sciences CorpCommon Stock · shares −8.7% · price +52.4%	6.9%	4.0%	$794.2M	16.0M	−8.7%	$49.51	$32.49	+52.4%	+$273.0M
2	ZoomCommon Stock · shares −2.5% · price −7.9%	6.2%	5.6%	$719.1M	10.6M	−2.5%	$67.74	$73.59	−7.9%	−$62.1M
3	TeslaCommon Stock · shares +13% · price −53.6%	4.9%	7.5%	$569.8M	4.6M	+13%	$123.18	$265.25	−53.6%	−$579.8M
4	BlockCommon Stock · shares −2.1% · price +14.3%	4.9%	3.5%	$565.8M	9.0M	−2.1%	$62.84	$54.99	+14.3%	+$70.7M
5	UiPathCommon Stock · shares −4.4% · price +0.8%	4.9%	4.1%	$559.9M	44.1M	−4.4%	$12.71	$12.61	+0.8%	+$4.4M
6	Roku IncCommon Stock · shares +1.7% · price −27.8%	4.3%	4.7%	$493.1M	12.1M	+1.7%	$40.70	$56.40	−27.8%	−$187.1M
7	Shopify IncCommon Stock · shares −8.6% · price +28.8%	4.0%	2.7%	$460.9M	13.3M	−8.6%	$34.71	$26.94	+28.8%	+$103.2M
8	Teladoc Health IncCommon Stock · shares −9.3% · price −6.7%	3.9%	3.7%	$447.7M	18.9M	−9.3%	$23.65	$25.35	−6.7%	−$32.2M
9	TwilioCommon Stock · shares +8.5% · price −29.2%	3.1%	3.3%	$362.8M	7.4M	+8.5%	$48.96	$69.14	−29.2%	−$137.8M
10	Intellia Therapeutics IncCommon Stock · shares −2.4% · price −37.7%	2.8%	3.8%	$328.7M	9.4M	−2.4%	$34.89	$55.96	−37.7%	−$198.5M
11	CoinbaseCommon Stock · shares +19% · price −45.1%	2.8%	3.5%	$325.2M	9.2M	+19%	$35.39	$64.49	−45.1%	−$224.6M
12	Beam Therapeutics IncCommon Stock · shares −3.3% · price −17.9%	2.8%	2.8%	$321.2M	8.2M	−3.3%	$39.11	$47.64	−17.9%	−$70.1M
13	Crispr Therapeutics AgCommon Stock · shares −4.9% · price −37.8%	2.8%	3.8%	$318.3M	7.8M	−4.9%	$40.65	$65.35	−37.8%	−$193.4M
14	Unity Software IncCommon Stock · shares −2.6% · price −10.3%	2.7%	2.5%	$313.7M	11.0M	−2.6%	$28.59	$31.86	−10.3%	−$35.9M
15	Draftkings IncCommon Stock · shares +1.3% · price −24.8%	2.5%	2.6%	$285.1M	25.0M	+1.3%	$11.39	$15.14	−24.8%	−$92.7M
16	Pagerduty IncCommon Stock · shares −6.7% · price +15.1%	2.3%	1.7%	$268.2M	10.1M	−6.7%	$26.56	$23.07	+15.1%	+$35.2M
17	Ginkgo Bioworks Holdings IncCommon Stock · shares +14% · price −45.8%	2.1%	2.8%	$244.0M	144.4M	+14%	$1.69	$3.12	−45.8%	−$181.4M
18	RobloxCommon Stock · shares −0.1% · price −20.6%	2.1%	2.1%	$240.9M	8.5M	−0.1%	$28.46	$35.84	−20.6%	−$62.5M
19	RobinhoodCommon Stock · shares −11% · price −19.4%	2.1%	2.3%	$238.1M	29.2M	−11%	$8.14	$10.10	−19.4%	−$57.3M
20	Pacific Biosciences Of CaliforCommon Stock · shares −10% · price +40.9%	1.8%	1.2%	$210.2M	25.7M	−10%	$8.18	$5.81	+40.9%	+$61.0M
21	Veracyte IncCommon Stock · shares −8.6% · price +43.0%	1.7%	1.1%	$197.0M	8.3M	−8.6%	$23.73	$16.60	+43.0%	+$59.2M
22	Twist Bioscience CorpCommon Stock · shares +0.4% · price −32.4%	1.4%	1.6%	$159.5M	6.7M	+0.4%	$23.81	$35.24	−32.4%	−$76.3M
23	10x Genomics IncCommon Stock · shares −5.7% · price +27.9%	1.4%	0.91%	$157.3M	4.3M	−5.7%	$36.44	$28.48	+27.9%	+$34.4M
24	Ionis Pharmaceuticals IncCommon Stock · shares −28% · price −14.6%	0.88%	1.1%	$101.0M	2.7M	−28%	$37.77	$44.23	−14.6%	−$17.3M
25	TrimbleCommon Stock · shares −6.2% · price −6.8%	0.84%	0.77%	$96.4M	1.9M	−6.2%	$50.56	$54.27	−6.8%	−$7.1M
	Total · 232 positions	100%		$11.54B						−$1.88B

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q3 2022 to Q4 2022: 226 stocks held throughout, down $1.88B (−14.3%).

Exact Sciences Corp+$273.0M+52%
Shopify Inc+$103.2M+29%
Block+$70.7M+14%
Pacific Biosciences Of Califor+$61.0M+41%
Veracyte Inc+$59.2M+43%
Roku Inc−$187.1M−28%
Crispr Therapeutics Ag−$193.4M−38%
Intellia Therapeutics Inc−$198.5M−38%
Coinbase−$224.6M−45%
Tesla−$579.8M−54%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$60.00B$30.00B$0

Q4 201639 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 14, 2026	$15.40B+20%	191	SEC ↗
Q1 2026	May 12, 2026	$12.86B−15%	182	SEC ↗
Q4 2025	Feb 11, 2026	$15.07B−10%	196	SEC ↗
Q3 2025	Nov 12, 2025	$16.80B+23%	196	SEC ↗
Q2 2025	Jul 30, 2025	$13.64B+37%	191	SEC ↗
Q1 2025	May 7, 2025	$9.99B−17%	196	SEC ↗
Q4 2024	Feb 4, 2025	$12.01B+10%	183	SEC ↗
Q3 2024	Oct 31, 2024	$10.93B−3%	194	SEC ↗
Q2 2024	Jul 26, 2024	$11.27B−22%	190	SEC ↗
Q1 2024	Apr 18, 2024	$14.44B−14%	230	SEC ↗
Q4 2023	Jan 17, 2024	$16.89B+29%	223	SEC ↗
Q3 2023	Oct 18, 2023	$13.07B−13%	226	SEC ↗
Q2 2023	Jul 10, 2023	$15.10B+4%	222	SEC ↗
Q1 2023	Apr 17, 2023	$14.55B+26%	221	SEC ↗
Q4 2022	Jan 24, 2023	$11.54B−20%	232	SEC ↗
Q3 2022	Oct 17, 2022	$14.35B−15%	250	SEC ↗
Q2 2022	Jul 11, 2022	$16.91B−29%	354	SEC ↗
Q1 2022	Apr 18, 2022	$23.96B−28%	353	SEC ↗
Q4 2021	Jan 28, 2022	$33.08B−21%	368	SEC ↗
Q3 2021	Nov 12, 2021	$41.64B−23%	300	SEC ↗
Q2 2021	Aug 5, 2021	$53.74B+7%	285	SEC ↗
Q1 2021	May 13, 2021	$50.34B+34%	290	SEC ↗
Q4 2020	Feb 12, 2021	$37.59B+123%	244	SEC ↗
Q3 2020	Oct 30, 2020	$16.86B+81%	223	SEC ↗
Q2 2020	Aug 11, 2020	$9.30B+132%	213	SEC ↗
Q1 2020	May 14, 2020	$4.01B+1%	207	SEC ↗
Q4 2019	Jan 31, 2020	$3.96B−13%	218	SEC ↗
Q3 2019	Nov 12, 2019	$4.58B+15%	224	SEC ↗
Q2 2019	Jul 30, 2019	$3.97B+13%	229	SEC ↗
Q1 2019	May 13, 2019	$3.50B+42%	196	SEC ↗
Q4 2018	Feb 11, 2019 (amended)	$2.46B−26%	194	SEC ↗
Q3 2018	Nov 7, 2018	$3.31B+21%	202	SEC ↗
Q2 2018	Aug 7, 2018	$2.73B+36%	200	SEC ↗
Q1 2018	May 14, 2018	$2.01B+60%	199	SEC ↗
Q4 2017	Feb 12, 2018	$1.26B+53%	200	SEC ↗
Q3 2017	Nov 9, 2017	$819.3M+60%	145	SEC ↗
Q2 2017	Aug 11, 2017	$513.6M+48%	109	SEC ↗
Q1 2017	May 15, 2017	$346.9M+26%	104	SEC ↗
Q4 2016	Feb 13, 2017	$274.9M	102	SEC ↗